Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Submitted by
admin
on January 17, 2017 - 10:18pm
Source:
Yahoo/Benzinga
News Tags:
Eli Lilly
baricitinib
rheumatoid arthritis
Headline:
Barictinib FDA Delay Only A 'Short-Term Setback' For Eli Lilly, Says Credit Suisse
Do Not Allow Advertisers to Use My Personal information
